Baillie Gifford & Co
SANA icon

Baillie Gifford & Co’s Sana Biotechnology SANA Stock Holding History

Baillie Gifford & Co’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,609,065
Closed -$19M – 286
2026
Q1 		$19M Hold
6,609,065
– – 0.02% 183
2025
Q4 		$26.9M Sell
6,609,065
-4,827,438
-42% -$21.6M 0.02% 176
2025
Q3 		$40.6M Buy
11,436,503
+1,371,775
+14% +$4.96M 0.03% 163
2025
Q2 		$27.5M Sell
10,064,728
-126,748
-1% -$262K 0.02% 175
2025
Q1 		$17.1M Sell
10,191,476
-42,097
-0.4% -$118K 0.01% 188
2024
Q4 		$16.7M Sell
10,233,573
-44,511
-0.4% -$133K 0.01% 190
2024
Q3 		$42.8M Sell
10,278,084
-293,116
-3% -$1.54M 0.03% 149
2024
Q2 		$57.7M Sell
10,571,200
-85,079
-0.8% -$678K 0.05% 135
2024
Q1 		$107M Buy
10,656,279
+506,262
+5% +$3.79M 0.08% 121
2023
Q4 		$41.4M Sell
10,150,017
-54,358
-0.5% -$200K 0.03% 157
2023
Q3 		$39.5M Sell
10,204,375
-631,786
-6% -$3.4M 0.04% 155
2023
Q2 		$64.6M Sell
10,836,161
-40,768
-0.4% -$235K 0.05% 137
2023
Q1 		$35.6M Buy
10,876,929
+112,202
+1% +$448K 0.03% 163
2022
Q4 		$42.5M Sell
10,764,727
-202,009
-2% -$988K 0.04% 151
2022
Q3 		$65.8M Sell
10,966,736
-44,726
-0.4% -$323K 0.07% 130
2022
Q2 		$70.8M Sell
11,011,462
-74,399
-0.7% -$474K 0.07% 137
2022
Q1 		$91.6M Sell
11,085,861
-176,169
-2% -$1.42M 0.06% 143
2021
Q4 		$174M Buy
11,262,030
+72,198
+0.6% +$1.39M 0.1% 115
2021
Q3 		$252M Sell
11,189,832
-52,019
-0.5% -$1.09M 0.13% 108
2021
Q2 		$221M Buy
11,241,851
+1,254,306
+13% +$28.4M 0.11% 121
2021
Q1 		$334M Buy
+9,987,545
New +$325M 0.19% 98

Other funds holding SANA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $10.6B AUM 19.73% 1-Year Est. Return

Baillie Gifford & Co's SANA Position: Q2 2026 in Review

Baillie Gifford & Co sold out of Sana Biotechnology (SANA) in Q2 2026, closing a stake of 6,609,065 shares — an estimated $19M sold.

Baillie Gifford & Co first reported a position in SANA in Q1 2021 and held it in 21 quarters. The position peaked at $334M in Q1 2021. 74 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • Baillie Gifford & Co reported no remaining Sana Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Baillie Gifford & Co sold 6,609,065 Sana Biotechnology shares in Q2 2026, an estimated $19M.
  • Baillie Gifford & Co first reported a position in Sana Biotechnology in Q1 2021 and held it in 21 quarters.
  • Baillie Gifford & Co's Sana Biotechnology position peaked at $334M in Q1 2021.
  • 74 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.